Personalized Postoperative Pain Management Following Thoracic Surgery in Adults

Condition(s) studied

Study summary

The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone, in adults following thoracic surgery. Major inpatient thoracic surgeries (TS) for lung disease are common and extremely painful surgeries and are associated with sever post-surgical pain, high incidence of chronic post-surgical pain (CPSP), excess opioid use, costly immediate postoperative opioid adverse events (AEs), and long hospital stays. This study is aiming to develop proactive risk prediction algorithms for precision surgical pain relief in adult TS patients through comparison of actual clinical outcomes with standard of care to predicted outcomes based on personalized risk assessments.

Eligibility

Primary outcome measure(s)

• Opioid-related Post-operative nausea and vomiting (PONV) — Post-operative up to 12 months
  PONV is measured with a binary yes/no response
• Opioid-related sedation — Post-operative up to 12 months
  Sedation will be measured using the Riker Sedation Scale. The minimum score of 1 categorizes the patient as being unarousable, while the maximum score of 7 categorizes the patient as being dangerous agitation.
• Opioid-related respiratory depression (RD) — Post-operative up to 12 months
  Respiratory depression is defined as abnormally slow respiratory rate which is below 12 breaths per minute. This will be measured with a binary yes/no response pulled from the electronic medical records.

Trial sites (4)

More OpalGenix, Inc trials in the USA

Other trials for the same condition